Increased libido in a woman treated with fluvoxamine: a case report

OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy. METHOD: Single case report. RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine. The increased libido disappeared after fluvoxamine was discontinued. CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.     

氟伏沙明治疗躯体形式障碍对照研究

目的 探讨氟伏沙明治疗躯体形式障碍的临床疗效及安全性.方法 将179例躯体形式障碍患者随机分为两组,研究组147例,口服氟伏沙明治疗;对照组32例,口服阿米替林治疗,观察6周.于治疗前及治疗1周、2周、4周、6周末采用汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组汉密顿抑郁量表、汉密顿焦虑量表评分均较治疗前有显著下降(P＜0.01),研究组治疗1周、2周末均较对照组下降显著(P＜0.01);治疗6周末,研究组总有效率89.4%,对照组为81.3%,两组总有效率差异无显著性(χ2=1.508,P＞0.05).研究组植物神经、心血管、神经系统的不良反应发生率及副反应量表评分均显著低于对照组(P＜0.05或0.01).结论 氟伏沙明治疗躯体形式障碍总体疗效显著,较阿米替林起效快、安全性高,依从性好.     

氟伏沙明与氯米帕明治疗强迫症的对照研究

目的比较氟伏沙明与氯米帕明治疗强迫症的疗效和不良反应。方法强迫症患者共64例，根据入组序号随机分为2组，疗程8周。应用恐怖／强迫量表（MSCPOR）、汉密尔顿焦虑量表（HAMA）评定疗效，TESS评价不良反应。结果氟伏沙明组治疗总有效率90．6％。氯米帕明组治疗总有效率84．3％，与氟伏沙明组相比差异无统计学意义（P〉0．05）。氟伏沙明治疗过程中出现药物不良反应较氯米帕明轻。结论氟伏沙明是一种治疗强迫症安全有效的药物。     

Chronic Tension-Type Headache, Mood Depression and Serotonin: Therapeutic Effects of Fluvoxamine and Mianserine

SYNOPSIS
Forty out-patients affected by chronic tension-type headache were selected according to the diagnostic criteria of International Headache Society (IHS) Headache Classification Committee. In a controlled trial patients received placebo for a four-week baseline period, then they were randomized in double-blind fashion to therapy with mianserine (30-60 mg/day) or fluvoxamine (50-100 mg/day) for another eight-week period. Frequency of headache, pain severity and analgesic consumption were evaluated using a self-monitoring system. Mood depression was evaluated at 0, 4 and 8 weeks by using Zung'ss Self-Rating Depression Scale and Hamilton Rating Scale for Depression. Both drugs were beneficial in the treatment of chronic tension-type headache. Non-depressed subjects with more severe headache responded best to fluvoxamine, whereas mianserine was more effective in the treatment of depressed patients with moderate headache. These results suggest that central serotoninergic neurotransmission can play a role in the pathophysiology of chronic tension-type headache also in non-depressed patients.     

Interaction between carbamazepine and fluvoxamine.

In 3 patients the addition of fluvoxamine to a constant dosage of carbamazepine (CZP) caused a substantial rise of plasma CZP accompanied by symptoms of intoxication. As this drug combination may occur increasingly in the future, this probably pharmacokinetic interaction is of practical relevance.     

Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study.

The efficacy of fluvoxamine on cognitive functioning and behavioral changes was evaluated in a double-blind, placebo-controlled study of 46 elderly demented patients. The patients had a DSM-III diagnosis of primary degenerative dementia or multi-infarct dementia and were aged greater than or equal to 65 years. Twenty-two patients were given 150 mg fluvoxamine per day and 24 received placebo tablets; 14 and 15 patients, respectively, completed 6 weeks of treatment. Within treatments, there were no significant changes in median scores on neuropsychological tests (picture recall and recognition, trail making and finger tapping) or the GBS scale scores (degrees of dementia) or GBS subscale score (clinical profiles, including symptoms common in dementia, motor, emotional and intellectual functioning). Between treatments, the median changes in psychometric test scores did not differ significantly. However, within and between treatments, there were trends favoring fluvoxamine on symptoms common in dementia (confusion, irritability, anxiety, fear-panic, mood level and restlessness). In conclusion, the study does not support the hypothesis that fluvoxamine improves cognitive functioning or behavioral changes in elderly dementia patients.     

Efficacy of combination treatment of fluvoxamine and tiapride for repetitive behaviors in frontotemporal lobar degeneration

The present study reports a 63‐year‐old right‐handed man with frontotemporal lobar degeneration (FTLD) who manifested severe repetitive and disinhibited behaviors. Combination treatment of fluvoxamine and tiapride decreased the frequency of these behaviors. The results indicate that these drugs are effective for the treatment of repetitive and disinhibited behaviors for patients with FTLD. The behaviors caused by FTLD are discussed in terms of obsessive–compulsive spectrum disorder.     

Adverse effects of long‐term administration of fluvoxamine on haematology,blood biochemistry and fertility in male albino rats: a possible effect of cessation

Fluvoxamine is recommended as first‐line treatment for a number of obsessive–compulsive disorders, anxiety disorders, social phobia, and post‐traumatic stress disorder and panic disorder. The adverse effects of prolonged oral administration of fluvoxamine on haematology, biochemical parameters and fertility in male rats were evaluated in this study. Sixty adult male rats were allocated into 5 equal groups and orally treated with fluvoxamine 9 mg kg^?1 b.wt. (low therapeutic dose, LTD) and 27 mg kg^?1 b.wt. (high therapeutic dose, HTD), while the control rats received 0.5 ml distilled water for a period of 8 weeks. The 4^th and 5^th groups were gavaged with LTD and HTD of fluvoxamine for 8 weeks and then left untreated for another 8 weeks (recovery groups). HTD of fluvoxamine induced leukocytosis, lymphocytosis and monocytosis. LTD and HTD of fluvoxamine evoked hepatic, renal and cardiac dysfunction. Moreover, fluvoxamine treatment might lead to the risk of male infertility, which is indicated by its deleterious impacts on spermiogram and steroidogenesis hormones. They also induced oxidative stress, apoptosis in testicular tissue. Fortunately, the previous alterations were mostly reversed during the recovery period.     

Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients

Aims:  Fluvoxamine, a selective serotonin reuptake inhibitor, is widely used to treat major depression. However, the symptomatological predictors of the response to fluvoxamine have not been studied.
Methods:  This study included 100 Japanese patients who fulfilled the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for the diagnosis of major depressive disorders and whose score on the Montgomery and Åsberg Depression Rating Scale (MADRS) was 21 or higher. Eighty-one patients were included. Patients with a pretreatment MADRS score of ≥31 were defined as 'severe' ( n  = 32) and the rest were defined as 'non-severe' ( n  = 49). The three-factor model of MADRS was used for analysis: the first factor was defined by three items, the second factor was defined by four items, and the third factor was defined by three items representing dysphoria, retardation, and vegetative symptoms, respectively. Fluvoxamine (100–200 mg/day) was administered twice daily for 6 weeks.
Results:  In the non-severe patients, the mean factor 3 score of the non-responders at pretreatment was significantly higher than that of the responders. However, a significant difference was observed in the mean factor 3 scores from 1 week onwards between the non-severe responders and non-responders. Furthermore, the fluvoxamine response rate in the severe patients was 75% and higher than that of the non-severe patients (65.3%).
Conclusions:  This study suggested that a low factor 3 score at pretreatment was a good predictor of the response to fluvoxamine in non-severe patients. The marked efficacy of fluvoxamine in the treatment of severe patients was also confirmed.